Using Henagliflozin to Reduce Heart Damage After Heart Attacks
Clinical Study on Reducing Myocardial Infarction Siez After Primary PCI in Patients With ST Segment Elevation Myocardial Infarction by Using Henagliflozin
This study is testing if the medication Henagliflozin can help reduce heart damage and improve recovery in people who have just had a heart attack.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06187727 on ClinicalTrials.gov |
What this trial studies
This randomized controlled intervention involves 240 patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who are scheduled for emergency percutaneous coronary intervention (PCI). Participants are divided into two groups: one receiving Henagliflozin orally for six months post-acute myocardial infarction and a control group. The study monitors dynamic changes in myocardial enzymes and assesses major cardiovascular events, including non-fatal myocardial infarction and hospitalization for heart failure, over a six-month follow-up period. The goal is to evaluate the effectiveness of Henagliflozin in reducing infarct size and improving left ventricular remodeling.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 who have experienced chest pain for less than 12 hours and are diagnosed with STEMI, planning to undergo primary PCI.
Not a fit: Patients with mechanical complications, cardiogenic shock, or other severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce heart damage and improve recovery outcomes for patients after a heart attack.
How similar studies have performed: Other studies have shown promise in using similar interventions for myocardial infarction, but this specific approach with Henagliflozin is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. STEMI patients with clear diagnosis: ischemic chest pain lasting for more than 30 minutes and adjacent to two or more leads of ST Segment elevation (limb lead ≥ 0.1mV, chest lead ≥ 0.2mV) with or without elevated myocardial enzyme levels; 2. Chest pain lasting less than 12 hours; 3. Age range from 18 to 80 years old; 4. Plans to undergo primary PCI ; 5. Informed consent form Exclusion Criteria: 1. Mechanical complications; 2. Cardiogenic shock; 3. Experienced myocardial infarction within 6 months; 4. Aortic dissection; 5. Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included 6. Urinary system infection
Where this trial is running
Beijing, Beijing
- Chinese PLA general hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Geng Qian, MD
- Email: qiangeng9396@263.net
- Phone: 086-13371665688
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.